How One Health System Is Embedding Diabetic Retinopathy Screening Into Primary Care
OhioHealth is scaling its use of Digital Diagnostics’ AI system that autonomously diagnoses diabetic retinopathy during primary care visits.
MedCity Pivot Podcast: Eye As the Window to Your Health With Vicky Demas
Vicky Demas, CEO of identifeye Health, talks about the company's approach to probe the retina with its proprietary device and companion algorithm. The reitna, she believes, holds the clues to overall health.
presented by
The Top-Rated Orthopedic Surgery Centers in the Houston Area and Beyond
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
Eyenuk’s New FDA Clearance Could Boost Adoption for Its Diabetic Retinopathy Screening Tech
Eyenuk recently received FDA clearance to use the Topcon NW400 retinal camera with its EyeArt AI system, which automatically detects diabetic retinopathy. The company said this FDA clearance makes its system the only AI system that is FDA-cleared for use with multiple retinal cameras produced by different manufacturers.
Eyenuk raises $26M for diabetic retinopathy screening tech
Eyenuk, a company that makes technology for eye screenings, raised $26 million in a Series A funding round, bringing its total funding to more than $43 million. Research shows that the company's AI system is more accurate in detecting diabetic retinopathy than a clinical examination from a general ophthalmologist or a retina specialist.
Medicare prices AI-based screening for diabetic retinopathy
The agency set a national payment amount for AI-based screenings for diabetic retinopathy in its 2022 Medicare Physician Fee Schedule final rule. It would also allow the screenings to count toward quality measures.
AbbVie makes another gene therapy move, paying $370M to partner with Regenxbio
AbbVie will take the lead on commercializing Regenxbio’s gene therapy in wet AMD and diabetic retinopathy. It’s AbbVie’s second major gene therapy deal this year, coming months after it committed $90 million to preclinical-stage Capsida Biotherapeutics.
presented by
The Top 6 Best Analytics Tools for Health Care Revenue in 2025
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
How to curb the high cost of diabetic eye disease
The Centers for Disease Control and Prevention found that diabetes-related blindness costs can total more than $500 million per year, but eye care screenings are one of the easiest and most cost-effective ways to detect diabetes early and get patients the treatment they need.
Google and Verily reveal algorithm for diabetic eye disease screening
The organizations have announced that the first real-world clinical use of the algorithm is happening at the Aravind Eye Hospital in Madurai, India.
IDx raises $33M Series A after its AI-powered screening tool received an FDA nod
The company's technology for screening diabetic retinopathy was granted "Breakthrough Device" designation and is able to provide a clinical decision, instead of simply a recommendation to the physician.
FDA greenlights tool for automated detection of diabetic retinopathy in primary care
The marketing clearance follows the FDA's decision to approve a "breakthrough device" designation for IDx-DR, accelerating the review process for the product based on its ability to address an unmet medical need.
presented by
How to Optimize Your Phlebotomy Setup for Efficient Patient Care
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
This AI screening tool for diabetic retinopathy makes a decision, not a recommendation
The system has an artificial intelligence algorithm that evaluates the images coming from the camera and determines whether or not there's diabetic retinopathy in them,” explained IDx Founder and President Michael Abràmoff. “So it makes a clinical decision, without someone like me being involved — it's fully autonomous.”